Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

Glucagon-like peptide-1 receptor agonists improve cardiovascular outcomes and reduce mortality in patients with type 2 ...

Global News Ozempic can help prevent limb loss in some patients living with peripheral artery disease, trial shows Posted: April 21, 2025 | Last updated: April 23, 2025 Semaglutide, more commonly ...

Semaglutide, more commonly known as Ozempic, can do more than help with weight loss. A new clinical trial shows it helps treat poor blood flow in diabetic patients, which could otherwise lead to arm ...

The table below is a review of notable updates that occurred in April 2025 for investigational products in development.

New findings from multiple studies demonstrate that glucagon-like peptide-1 receptor agonists (GLP-1RAs), a class of ...

Semaglutide (Novo Nordisk) Glucagon-like peptide-1 receptor agonist To improve walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease. Phase 3 results VERVE ...

Novo Nordisk's Ozempic has been shown to improve waking distance and quality of life in people with type 2 diabetes (T2D) and peripheral artery disease (PAD), potentially adding yet another ...